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Abstract 8 
Nipah virus is an emerging, highly pathogenic, zoonotic virus of the paramyxoviridiae family. Human 9 
transmission occurs by close contact with infected animals, the consumption of contaminated food, or, 10 
occasionally, via other infected individuals. Currently, we lack therapeutic or prophylactic treatments 11 
for Nipah virus. To develop these agents we must now improve our understanding of the host-virus 12 
interactions that underpin a productive infection. This aim led us to perform the present work, in which 13 
we identified (101) human-Nipah virus protein-protein interactions (PPIs), most of which (88) are 14 
novel. This dataset provides a comprehensive view of the host complexes that are manipulated by viral 15 
proteins. Host targets include the PRP19 complex and the miRNA processing machinery. Furthermore, 16 
we explored the biologic consequences of the interaction with the PRP19 complex and found that the 17 
Nipah virus W protein is capable of altering p53 control and gene expression. We anticipate that these 18 
data will help in guiding the development of novel interventional strategies to counter this emerging 19 
viral threat. 20 
 21 
Importance 22 
Nipah virus is recently discovered virus that infects a wide range of mammals, including humans. Since 23 
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its discovery there have been yearly outbreaks and in some of them the mortality rate has reach 100% 24 
of the confirmed cases. However, the study of Nipah virus has been largely neglected and currently we 25 
lack treatments for this infection. To develop these agents we must now improve our understanding of 26 
the host-virus interactions that underpin a productive infection. In the present work we identified 101 27 
human-Nipah virus protein-protein interactions using an affinity purification approach coupled with 28 
mass spectrometry. Additionally, we explored the cellular consequences of some of these interactions. 29 
Globally, this dataset offers a comprehensive and detailed view of the host machinery's contribution to 30 
the Nipah virus's life cycle. Furthermore, our data present a large number of putative drug targets that 31 
could be exploited for the treatment of this infection. 32 
 33 
Introduction 34 
Nipah virus is an emerging, highly pathogenic, zoonotic virus from the paramyxoviridiae family (1, 2). 35 
The virus was first detected in humans in 1998, in Malaysia (3), and since then fatal cases have been 36 
reported yearly. The first outbreaks in Malaysia and Singapore were associated with severe febrile 37 
encephalitis with a case fatality rate of 38%. More recent outbreaks in Bangladesh and India are linked 38 
with respiratory disease and manifest an even higher case fatality rate, that occasionally reaches a 39 
staggering 100% (4). Transmission to humans occurs mostly by close contact with infected animals or 40 
by consuming contaminated food (5). However, incidents of human-to-human transmission have also 41 
been reported (6), with these being the major route of infection for the Bangladeshi strains (7). 42 
Currently, there are neither therapeutic nor prophylactic treatments for Nipah virus. Despite the low 43 
number of annual cases, the virus's broad host range and increased pathogenesis warrants attention 44 
given the major health threat that this virus could pose. However, disappointingly, the study of Nipah 45 
virus has been largely neglected.   46 
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The Nipah virus comprises a 6-gene, 18.2 Kb, negative ssRNA genome, which encodes 9 proteins: 48 
Nucleoprotein (N), Phosphoprotein (P), the interferon antagonists W and V, the viral C protein, a 49 
matrix protein (M), viral fusion and glycoproteins (F and G, respectively), and a large polymerase (L). 50 
Host attachment is achieved by the viral G protein that binds to the host cell surface receptors ephrin 51 
B2 or B3 (8, 9). Next, the cellular and viral membranes fuse and the capsid disassembles to deliver the 52 
viral genome into the cell. Once in the cytoplasm, the viral messenger and genomic RNAs are 53 
synthesized and translated to generate viral proteins. Successful infection requires evasion of the 54 
interferon (IFN)-α/β response (10, 11) (a key component of the innate immune response to virus 55 
infection). Four Nipah-encoded proteins (P, V, W, and C, all encoded by the P gene) participate in 56 
overcoming the innate immune response (12, 13). The generation of these proteins relies on varying the 57 
reading frame, or using an alternate reading frame when transcribing P. In order to vary the reading 58 
frame, the fidelity of transcription is interrupted. Specifically, the polymerase stutters at an AG patch of 59 
sequence, which results in the insertion of supplementary G residues into the nascent mRNA. While the 60 
unedited P mRNA encodes the P protein, insertion of one or two extra G residues shifts the frame to 61 
produce the V and W proteins, respectively; the C protein is synthesized from an alternate open reading 62 
frame (14). A large proportion of the P, V, and W protein sequences are identical (406 amino acids of 63 
709, 456, and 449 amino acids, respectively) and, consequently, share some functions. All three 64 
proteins inhibit the Jak-STAT signaling pathway by binding to STAT1 and preventing its 65 
phosphorylation in response to IFN (15–18). In addition, the V protein inhibits MDA5 signaling (which 66 
is conserved across paramyxoviruses) (19–21), while the W protein blocks Toll-like receptor (TLR) and 67 
Rig-I-like receptor (RLR) signaling (downstream of IFN regulatory factor 3 activation) (22). The 68 
different functions of the V and W proteins can be attributed to their sequence differences and distinct 69 
sub-cellular localizations. While V is mostly cytosolic, W is conveyed to the nucleus by virtue of a 70 
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nuclear localization signal (NLS) at its unique carboxy terminus (Ct). In addition to the proteins 71 
encoded by the P gene, the M proteins have also been reported to be involved in antagonizing the 72 
innate immune system by targeting TRIM6, IKK, and unanchored polyubiquitin chains (23).  73 
  74 
Identifying and understanding host-virus interactions are fundamental to our comprehension of the 75 
mechanism of infection, and how this can be used to inform the development of vaccines or antivirals. 76 
Previously, a variety of technologies have been used to identify host-virus protein-protein interactions 77 
(PPIs). These include tandem-affinity purification (TAP) coupled with mass spectrometry (MS) (TAP-78 
MS) (24, 25), two-hybrid system screens (26), or protein-fragment complementation assays (27). The 79 
TAP-MS approach, particularly for a biosafety level 4 (BSL4) pathogen, such as Nipah virus, offers 80 
significant advantages. First, TAP-MS is a sensitive and unbiased method with which to identify PPIs. 81 
Second, the expression, purification, and identification of PPIs for individual viral proteins constitutes a 82 
risk-free and laboratory-friendly approach. Third, the resultant dataset should provide a comprehensive 83 
analysis of the complexes that are formed, and the pathways that are triggered during the viral life 84 
cycle. However, TAP-MS of non-cellular genes expressed from a plasmid driven system does not fully 85 
recapitulate the viral context and might lead to an erroneous identification of PPI.  86 
 87 
In the present work, we aimed to identify the human proteins associated with Nipah virus proteins 88 
using a TAP-MS approach. We identified 101 PPIs, 88 of which were previously unreported. We 89 
uncovered a number of host complexes targeted by the virus, including interactions with the PRP19 90 
complex and miRNA processing machinery. Furthermore, we explored the biologic consequences of 91 
these PPIs and found that the Nipah virus W protein is capable of altering p53 control and gene 92 
expression. Globally, this dataset offers a comprehensive and detailed view of the host machinery's 93 
contribution to the Nipah virus's life cycle. Furthermore, our data present a large number of putative 94 
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drug targets that could be exploited for the treatment of this life-threatening infection. Nonetheless, 95 
before drawing any conclusions on the functional relevance of any of these interactions results must be 96 
validated in a viral context. 97 
 98 
Results 99 
Purification, identification, and analyses of human-Nipah virus PPIs. To identify human proteins 100 
associated with Nipah virus we cloned the sequence of each known Nipah virus protein using a 101 
mammalian expression vector. Each protein was fused to a TAP tag (comprising 2xStrepII and 1xFlag) 102 
(28) at either its amino (Nt) or carboxy (Ct) terminus. Independent tags at either terminus were used to 103 
minimize the possibility of missing a PPI due to tag-masking. This strategy also allowed us to identify 104 
which protein end, if any, was prone to the interaction. Enhanced Yellow Fluorescent Protein (EYFP, 105 
Aequorea victoria), the Red Fluorescent Protein (RFP, Discosoma sp.), and an empty vector were 106 
included as negative controls. Clones were transfected into HEK-293T cells, with tagged proteins 107 
purified 48 hrs post transfection using, in tandem, the Streptavidin and Flag affinity labels. Final 108 
eluates were then analyzed by SDS–polyacrylamide gel electrophoresis for quality control, and by MS 109 
to identify interaction partners (Fig. 1a). After careful evaluation, the L protein derived samples were 110 
not submitted for MS analysis due to insufficient protein. Fusion of the C protein to EYFP was used to 111 
improve purification yields prior to PPI identification by MS. See materials and methods for a complete 112 
list of the constructs used and the number of replicates analyzed by MS. For each bait, only proteins 113 
identified in two or more replicates were considered to be potential interactors. Further, protein hits 114 
identified in any of the control experiments (using EYFP, RFP, or empty plasmid) were discarded. To 115 
further eliminate artifacts we compared our hits to those recorded in the CRAPome database (29), 116 
which lists affinity purification contaminants. Specifically, the experimentally obtained ratio for a 117 
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protein hit (i.e. the number of times a protein was identified with a particular bait/ replicate number (for 118 
that bait)) had to exceed that recorded in the CRAPome database by (at least) five fold. The abundance 119 
of the interaction was then estimated using the exponentially modified Protein Abundance Index 120 
(emPAI). To compare protein abundance across experiments, emPAIs for each protein were divided by 121 
the median emPAI value for the sample (emPAI/med). Since some hits were obtained in 2, 3, 4, or even 122 
in 5 replicates, to accurately evaluate their abundance, we calculated the average logarithm of the 123 
emPAI/med (ave log(emPAI/med)). As expected, the higher the number of times a protein was found, 124 
the higher its ave log value (emPAI/median; Fig. 1B, the unique PPI identified in 5 replicates is not 125 
represented in the bar graph). These data suggested a robust protein identification and selection 126 
protocol. A total of 101 PPIs were identified between human and Nipah virus proteins (Table 1) of 127 
which 88 were previously unreported. As we had placed the TAP tag at the N and C termini of the bait 128 
constructs we could analyze which position, if any, favored the detection of the interactor proteins. 129 
Overall, 64.4% of the interactors were identified irrespective of tag position, while 18.8% and 16.8% of 130 
the PPIs were identified, exclusively, when the affinity tag was either N- or C- terminal, respectively 131 
(Fig. 1C). For some Nipah virus proteins the tag position was irrelevant in terms of identifying partner 132 
proteins (e.g. for the P, V, and W proteins) (Fig. 1C). For other Nipah proteins (C, and in particular, G), 133 
the location of the affinity label greatly influenced the host protein-bait interaction. Interestingly, three 134 
of these proteins (F, G, and C) associate with cellular membranes. It is worth noting that, for proteins 135 
detected in two replicates, the ave log (emPAI/med) values were higher when identification was tag-136 
position dependent (Fig. 1B).  137 
  138 
Next, we analyzed the functional categories of host proteins associated with each Nipah virus bait. 139 
Based on the current literature, certain results were anticipated. These included an association of the F 140 
protein with the endoplasmic reticulum (30), and the G protein with the Ephrin receptor pathway (8). 141 
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The nuclear localization of W (18), the shuttling of protein C between the cytoplasm and nucleus (31), 142 
and the association of M with the ubiquitin machinery (23, 32), were all consistent with previous data 143 
(Figs. 1D and E). Conversely, some other highly enriched categories were unexpected. These included 144 
an association of the PRP19 complex with the P, V, and W proteins, and the enrichment of RNAi 145 
related proteins in the M-interactor list. Furthermore, a careful review of the literature revealed that 146 
36.4% of the hits had previously been reported as viral protein interactors (Fig. 1F). When a random 147 
list of 101 proteins was queried, only 8% were described as viral interactors (Fisher-test enrichment 148 
Log2 p-value= -17.14). The identification of known functions of Nipah virus proteins using GO term 149 
analyses, and the elevated percentage of hits previously associated with viral functions, greatly 150 
increases our confidence in this dataset.  151 
  152 
One of the main objectives of our work was to identify potential drug targets for the treatment of Nipah 153 
virus. With this in mind, we searched for drugs that could target any of the proteins obtained in our 154 
TAP-MS analyses. To this end we utilized the DRUGBANK database (a bioinformatics and 155 
cheminformatics resource that combines drug data (i.e. chemical, pharmacological and pharmaceutical) 156 
with comprehensive drug target information (i.e. sequence, structure, and pathway)) (33, 34). In our 157 
search we identified 11 drugs (including FDA approved compounds) that could target the Nipah virus's 158 
cellular interactors. These data are summarized in Table 2. 159 
  160 
To visualize these host-virus interactions we plotted the 101 PPIs as a network schematic (Fig. 2), with 161 
inclusion of the PPIs for cellular proteins derived from the IntACT (https://www.ebi.ac.uk/intact/) (35) 162 
and String databases (http://string-db.org/) (36) (dotted lines, Fig. 2). Collectively, the network contains 163 
93 nodes (corresponding to human and Nipah virus proteins) and 126 interactions (edges). Many of the 164 
known PPIs (involving the viral G, F, M, W, and V proteins) were identified in our assays (denoted by 165 
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the double black lines) (8, 9, 21, 22, 32, 37–42) and support the quality of our approach. Surprisingly, 166 
we also detected an interaction between the W protein and STAT4, although a previously reported 167 
interaction with STAT1 went undetected (Shaw et al. (18)). To confirm the potentially new interaction, 168 
we performed a pull-down experiment using V, W, VG121E, and WG121E protein lysates (the mutants 169 
cannot bind STAT1 (43)) with the resolved proteins probed for STAT1 and STAT4 expression. EYFP 170 
was included in the assay as a negative control. The experiments revealed strong interactions between 171 
the wild type V and W proteins and both STATs 1 and 4 (Fig 3). Conversely, neither VG121E nor WG121E 172 
bound either STAT. 173 
 174 
Interaction of the Nipah virus with the PRP19 complex. The network map helped to identify robust 175 
associations between the P, V, and W proteins and the PRP19 complex (Fig. 2 and Fig. 4A and B). The 176 
PRP19 complex (also known as PRPF19 or the NeeTeen Complex (NTC)) participates in key cellular 177 
processes (for a full review on PRP19 complex functions see (44)) that include splicing (45), 178 
transcription elongation (46), and genome maintenance (47). Additionally, the PRP19 complex has 179 
been identified as a negative regulator of p53 (48, 49). First, we sought to validate the PRP19-viral PPI 180 
identified in the TAP-MS experiments. Using the TAP tag, we pulled-down both the V and W proteins 181 
(and EYFP) and then performed immuno-blots for select PRP19 complex constituents (namely 182 
CDC5L, PRP19, PLRG1, and BCAS2; Fig. 4C). Mutants (G121E) of the Nipah virus V and W proteins 183 
were also included in this assay. Subsequent results confirmed the TAP-MS data, with an association 184 
between the viral proteins and the PRP19 complex detected, even in the presence of mutants deficient 185 
in STAT1 binding (VG121E and WG121E).  186 
  187 
The PRP19 complex manifests multiple activities in the nucleus. On the basis of Nuclear Localization 188 
Signal (NLS) expression, only the Nipah virus W protein (of all the proteins encoded by the P gene) is 189 
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predicted to be able to access this compartment. A robust nuclear co-localization between PLRG1 190 
tagged with Yellow Fluorescent Protein (YFP) and the W protein was detected (Fig. 4D). When the 191 
viral V or P proteins were co-expressed with YFP-PLRG1, only marginal co-localization at the peri-192 
nuclear region could be detected (Fig. 4D, arrowheads). These results suggest that the strong 193 
interactions seen in the TAP-MS experiments between PRP19 and the V and P proteins might have 194 
occurred post lysis following disruption of the cellular nuclear envelope.  195 
  196 
Next, we sought to discover whether the Nipah virus could interfere with the biologic functions of the 197 
PRP19 complex. First, we analyzed the activity of p53 in the presence of viral proteins. For this 198 
purpose we used a luciferase-based p53-activity reporter assay (50). Briefly, a reporter plasmid 199 
containing a p53 DNA-binding site upstream of a luciferase reporter was co-transfected with the 200 
protein of interest into HCT116 cells (a human-derived cell line that retains p53 activity); EYFP was 201 
used to normalize the data (white bar panel a). Interestingly, transfection and expression of the Nipah 202 
virus W (black bar, panels A, B and C) protein rendered higher luciferase values than EYFP (Fig. 5A). 203 
Conversely, transfections with P or V failed to alter p53 activity, as may be predicted from their 204 
cytosolic expression patterns and showed luciferase values significantly lower that those obtained with 205 
W. However, based on our TAP-MS data, both the Nipah virus V and P proteins are capable of 206 
interacting with the PRP19 complex if present in the same compartment/space (as occurred post lysis). 207 
When we altered the expression pattern of the V protein by supplementing its sequence with an NLS 208 
(VNLS) (22) we observed an increase in p53-dependent luciferase expression. Conversely, elimination 209 
of the NLS in the W protein (WBR34 (22)) reduced p53 activity back down. In accordance with our pull-210 
down assays, the elimination of STAT1 binding failed to influence the effects of the Nipah virus V or 211 























To analyze the role of Nipah virus W protein on p53 activity in the presence of stress/apoptotic stimuli, 214 
HCT116 cells were either treated with Doxorubicin (a known inducer of p53 activity (51)) or were 215 
infected with Newcastle disease virus (NDV). NDV is a -ssRNA paramyxovirus with a genome 216 
structure similar to Nipah (52), that has been used for functional studies of Nipah virus proteins (13). 217 
Irrespective of the cellular stress (infection or apoptosis; Figs. 5B and C), the EYFP-associated values 218 
were higher than those for the mock treated samples, confirming that p53 activity had been stimulated 219 
by the selected stimuli. In the cell stress scenarios (including viral infection), the Nipah virus W protein 220 
further enhanced p53 activity with nuclear localization of the W or V proteins key in achieving this 221 
activation, as confirmed in A549 cells (Fig. 5 D-F).  222 
  223 
Next, we decided to investigate the potential influence of the Nipah virus W protein on PRP19 224 
complex-mediated gene expression and splicing. Briefly, W protein-Firefly luciferase (Luc, negative 225 
control) dual expression plasmid EYFP constructs were transfected into HEK293T cells, and, 48 hrs 226 
later, EYFP positive cells were sorted and incubated (48 hrs) prior to extracting and sequencing 227 
mRNAs (Fig. 6A). This process was repeated in triplicate for each sample (GEO accession number: 228 
SRP116105). The consistency of replicate data is highlighted by the Pearson correlation analysis in 229 
which each set of three replicates can be seen clustered together (Fig. 6B). First, we assessed the 230 
differentially expressed genes, identifying 216, 708, and 308 differentially expressed genes using the 231 
Cuffdiff, EdgeR, and DESeq2 algorithms, respectively (53–55) (Fig. 6C). For subsequent analyses we 232 
considered only the 114 genes identified by all three algorithms (Figs. 6C and D; Supplementary Table 233 
1). The differential gene expression for W vs. Luc samples identified by RNA seq was then validated 234 
by qRT-PCR (Fig. 6E). To accomplish this, we selected representative genes that were either down-235 
regulated (INHBA and HSP6) or upregulated (WFIKKN2, MUC19, and OR2B67). Interestingly, a GO 236 
analysis of the 114 differentially expressed genes (W vs. Luc) revealed strong enrichment for terms 237 
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associated with DNA packing, stability, and innate immune defense (Table 3). These data suggest that 238 
the W protein interferes with the PRP19 complex in terms of genomic maintenance, or disrupts the 239 
innate antiviral response by altering gene regulation. Next, we sought to study the influence of nuclear 240 
localization on gene expression. Briefly, 48 hrs after transfecting HEK293T cells with W, V, or 241 
luciferase, mRNAs were extracted and the expression levels of INHBA and MUC19 analyzed by qRT-242 
PCR. Despite an experimental design that excluded the selection of EYFP positive cells, and was 243 
restricted to a 48 hr incubation post-transfection, the Nipah virus W protein induced a down-regulation 244 
of INHBA and up regulation of MUC19 (vs. the luciferase samples). In accordance with the p53 activity 245 
assay results, the V protein was incapable of altering the expression of any of the selected genes (Fig. 246 
6F), indicating that nuclear localization is essential if gene expression is to be altered. Analyses of the 247 
differentially expressed transcripts (Supplementary Table 2), together with the variation in transcript 248 
abundance (Fig. 6G) for W vs. Luc, did not suggest a modification of cellular splicing in the presence 249 
of the Nipah virus W protein.  250 
 251 
DICER1-TARBP2 interactions with Nipah virus matrix protein. We were also extremely interested 252 
in the putative interactions identified in the TAP-MS experiments between the Nipah virus M protein 253 
and the DICER1-TARBP2 complex (Fig. 2 and Fig. 7A). DICER1 participates primarily in the 254 
biogenesis of (multiple classes of) small RNAs including miRNAs (56). However, other functions have 255 
been attributed to this complex that include the processing of tRNAs and exogenous RNAs (57). To 256 
corroborate our TAP-MS data we transfected HEK293T cells with the TAP-tagged versions of the M 257 
(Nt and Ct tagged) and the V protein, After  24 hrs, endogenous DICER1 was immunoprecipitated and 258 
probed with the Flag tag (inversely to the MS-TAP approach where the bait was the Nipah M protein) 259 
(Fig. 7B left panel). Experiment that was repeated with HA-tagged M or V plasmids and including RFP 260 
as an additional negative control (Fig. 7 middle and right panels). As in the TAP-MS experiments, N-261 
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terminal tagged M was found to interact with DICER1 (Fig. 7B). At this point, we asked whether the 262 
Nipah virus M protein could influence DICER1 function. However, a luciferase-based DICER1 activity 263 
assay, with maturation analyses of exogenous miRNAs (Figs. 7C and D, respectively), showed that the 264 
M protein had no influence on the canonical functions of DICER1. Nonetheless, a role for M protein in 265 
other DICER1-TARBP2 activities cannot yet be ruled out. 266 
 267 
Discussion 268 
Currently, only a few sporadic cases of Nipah virus human infection are reported each year. However, 269 
the potential for human-to-human transmission, and an elevated pathogenicity, makes this virus a major 270 
potential global health threat. Accordingly, Nipah virus has been classified as a biosafetely level 4 271 
(BSL4) pathogen. Surprisingly, few efforts have been made towards the development of a therapeutic 272 
or prophylactic treatment. In terms of antivirals, there are two main approaches. Historically, 273 
virologists have focused on the design of compounds that target viral proteins, and this approach has 274 
seen many successes. However, this strategy can present some disadvantages. For example, rapidly 275 
evolving viruses, such as RNA viruses, may develop drug resistance over a relatively short time period. 276 
In some cases (e.g. the neuraminidase inhibitors of the Influenza A virus) the antiviral compound 277 
interferes with a viral protein/process at a late stage of the viral life cycle. This type of late blockade 278 
can severely reduce drug efficacy and narrow the treatment window. These and other hurdles have 279 
prompted a strategic shift towards examining, and potentially targeting, host-proteins that are 280 
manipulated by the virus in order to fulfill a productive viral life cycle. By interfering with these 281 
interactions, either functionally (i.e. disrupting the host protein function) or upstream, by blocking the 282 
host-pathogen PPI, viral propagation might be reduced or even stopped. In the current work, we 283 
focused on identifying PPIs between human proteins and the Nipah virus. Our detailed TAP-MS 284 
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analyses revealed 101 PPIs, most of them previously unreported. These interactions represent a 285 
valuable set of potential drug targets for the treatment of Nipah virus infection. Further, by utilizing the 286 
DRUGBANK database we could explore the drug-ability of our interactor dataset, and provide a list of 287 
potential strategies to counter viral infection. It is important to mention that the experiments presented 288 
in this work were not conducted in a viral infection context. Transient expression from a plasmid-289 
driven system yields large quantities of proteins which might alter the cellular interactome. Therefore, 290 
any result should be validated in a viral context before the functional relevance of the described PPIs is 291 
concluded.  292 
 293 
The Nipah virus W protein participates in evading the innate immune response by binding STAT1 and 294 
preventing its phosphorylation in response to IFN. Additionally, protein W has been reported to block 295 
the TLR and RLR pathways. Here, we report a previously undetected interaction between the Nipah 296 
virus W protein and the PRP19 complex. Most likely, this interaction occurs through the N terminal 297 
region of the protein that is shared with the V and P proteins. All three proteins (W, V, and P) have the 298 
potential to interact with the PRP19 complex, as shown by our TAP-MS experiments. However, in vivo, 299 
only the W protein was able to co-localize with PLRG1 (a member of the PRP19 complex). 300 
Furthermore, only the Nipah virus W protein was capable of modulating cellular processes that are 301 
controlled (partially) by the PRP19 complex. These results indicate that the interactions between P, V, 302 
and the PRP19 complex that were captured in our MS-TAP and pull-down assays, may have occurred 303 
post cell lysis. 304 
  305 
Our results showed a change in p53 activity and gene expression in the presence of the Nipah virus W 306 
protein. These changes correlate with the nuclear localization of the protein, as analyses of mutated V 307 
and W proteins revealed. The Nipah virus V protein, despite its capacity to interact with the PRP19 308 
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complex, could neither alter p53 activity nor gene expression when compared to controls. However, 309 
when localized to the nucleus, we detected a restoration of the ability of the V protein to activate p53.  310 
  311 
We should mention that our RNA sequencing data (differential expression of transcripts, and transcript 312 
abundance for W vs. Luc samples) suggested no major modification of cellular splicing in the presence 313 
of W. Nonetheless, collectively, our data indicates that the Nipah virus W protein is capable of altering 314 
the function of the PRP19 complex, and that its nuclear localization is required for this activity. 315 
Furthermore, the binding of STAT1 does not seem to be related to these effects, as indicated by our 316 
analyses of the STAT1 binding deficient V and W proteins. These data suggest that further analyses of 317 
the persistence of the protein W-PRP19 complex interaction, in the context of a viral infection, are now 318 
warranted.  319 
 320 
Due to the multi functionality of the PRP19 complex, it is currently impossible to pinpoint (with the 321 
present data) which of its multiple functions the virus is manipulating. Many viruses modulate the 322 
cellular apoptotic response (58) and it is possible that Nipah virus could, at some point during its life 323 
cycle, induce apoptosis by interfering with a negative regulator of p53 such as the PRP19 complex. 324 
There is also an extensive literature on the viral modulation of cellular gene expression. The Nipah 325 
virus interaction with PRP19 might represent an additional level of control over the cellular antiviral 326 
response. Whether this gene regulation is specific for a particular set of genes or is dependent on the 327 
genes expressed in the infected cell cannot yet be deduced (with the current data). It would be useful to 328 
investigate the influence of the W protein on gene expression in cells treated with IFN or stimulated 329 
with viral RNA. GO enrichment analyses revealed that the differentially expressed genes are linked 330 
with the innate immune response, which leads us to think that the Nipah virus is selectively hampering 331 
the cellular response to viral infection. However, besides the defense response, the gene set analyzed 332 
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seems to participate in DNA packing, chromatin organization, and silencing, which could indicate an 333 
indirect mechanism of altering the cellular response to viral infection. Since the PRP19 complex is 334 
heavily involved in genome maintenance and DNA stability (47), an enrichment of GO terms related to 335 
those functions could reflect the cellular response to the Nipah virus protein W - PRP19 complex 336 
interaction.  337 
 338 
Finally, we focused on the DICER1-Nipah M PPI. This interaction was confirmed by the pull-down 339 
(PD) of endogenous DICER1 in the presence of TAP-tagged Nipah virus M protein and V protein (as a 340 
negative control). As expected, only Nt tagged Nipah virus M protein could be seen interacting with 341 
DICER1. To corroborate this result the DICER1 PD was repeated in the presence of the HA-tagged 342 
versions of the Nipah virus M protein and using the RFP and Nipah virus V protein as a negative 343 
controls. Once again, only the Nt tagged forms of the Nipah virus M protein were PD together with 344 
DICER1. However, when DICER1 activity, in terms of miRNA production, was assessed in the 345 
presence of protein M we detected no noticeable effects. Nonetheless, DICER1 has been described to 346 
participate in other functions. In a Nipah virus infection, DICER1 could conceivably act as a pattern 347 
recognition receptor, as described in (59). In that context, the interaction of Nipah virus M with DICER1 348 
could prevent the cellular recognition of the virus without altering DICER1's canonical function.  349 
 350 
Our work suggests multiple new strands of research. Not only do we describe new PPIs between the 351 
Nipah virus and host, but we also identify new functions for the viral W and M proteins. These data 352 
constitute a significant advance in our understanding of Nipah virus biology and we anticipate that 353 























Materials and methods 356 
Protein expression and purification. For the identification of Nipah-human PPIs, DNAs encoding 357 
each viral protein fused to a TAP tag sequence at either the amino- or carboxy- terminus were 358 
transfected into HEK293T cells. Briefly, 30 μg of DNA were added to 1.5 mL of Opti-MEM medium 359 
(Gibco) (solution A). Separately, 1.5 mL Opti-MEM was supplemented with Lipofectamine 2000 (Life 360 
technologies; 2 μL/μg DNA, solution B). Solutions A and B were then mixed and incubated at room 361 
temperature for at least 10 minutes. The mixture was then overlaid onto a 15 cm tissue culture dish. 362 
Approximately 24 hours post transfection, cells were harvested and washed with PBS (x3). Cells were 363 
then lysed with 300 μL of Lysis Buffer (30 mM Tris-HCl, 150 mM NaCl, 0.5 % NP-40, Protease 364 
inhibitor (cOmplete Protease Inhibitor Cocktail, Roche) and phosphatase inhibitor (PhosSTOP, 365 
Roche)), and the lysate passed through a 30-gauge syringe (x3). The cell extract was clarified by 366 
centrifugation (10 minutes 10,000 g) and the supernatant transferred to a new tube. Tandem affinity 367 
purification (TAP) was as described in (28). Briefly, Nipah proteins were transiently expressed (24-30 368 
hrs) in HEK293T cells. Next, cells were lysed and viral proteins purified usind the Strep and Flag tags 369 
in tamdem. Protein digestion and identification (LC MSMS using an LTQ Orbitrap) was completed by 370 
the W.M. Keck Biotechnology Resource Laboratory (http://medicine.yale.edu/keck/index.aspx). 371 
Constructs analyzed by MS (# replicates): Empty (2), Nt-EYFP (2), EYFP-Ct (2), Nt-RFP (1), RFP-Ct 372 
(1), Nt-N (3), N-Ct (3), Nt-P (2), P-Ct (2), Nt-V (2), V-Ct (2), Nt-W (2), W-Ct (2), Nt-EYFP-C (2), C-373 
EYFP-Ct (2), Nt-M (2), M-Ct (2), Nt-F (2), F-Ct (2), Nt-F + F-Ct (1*), Nt-G (2), G-Nt (2), Nt-G + G-374 
Ct (1*).  * Nt and Ct plasmids were mix (1:1). This samples were not included in the analysis of the tag 375 
position. 376 
 377 
Selection criteria and the abundance of interacting proteins.  378 
 on S
eptem



















The MS data were filtered according to the following selection criteria. All pseudo genes, predicted 379 
proteins, and immunoglobulin fragments were discarded. Common contaminants in MS experiments 380 
such as Keratins and Trypsins were also eliminated. Next, those proteins purified with any of the 381 
negative controls (EYFP, RFP, or empty plasmid) were deleted. To further eliminate common artifacts 382 
we utilized the CRAPome database (29) of common protein contaminants (i.e. identified from negative 383 
control experiments) identified in affinity purification experiments followed by MS. Only those 384 
proteins with an experimentally obtained found/total ratio >5x CRAPome (ratio) were selected. Finally, 385 
proteins that interacted with 3 or more Nipah virus proteins were discarded as contaminants from the 386 
experimental conditions used in the affinity purification (in this analysis, the sequence similarities for 387 
the viral P, V, and W proteins, led these to be assessed collectively (i.e. as one)). The abundance of each 388 
interaction was estimated using the exponentially modified Protein Abundance Index (emPAI). The 389 
emPAI value offers an approximate, label-free, quantification of the proteins in a mixture based on 390 
protein coverage obtained by peptide matches in a database search (60). To compare the intensities 391 
across experiments the emPAIs for each protein were divided by the median emPAI value of the sample 392 
(emPAI/med). As some hits were obtained 2, 3, 4, or up to 5 times, comparisons were made using the 393 
average log (emPAI/med).  394 
 395 
Cell culture. Colon epithelial carcinoma cells (HCT116), human alveolar epithelial cells (A549), and 396 
human embryonic kidney 293T (HEK293T) cells were obtained from the American Type Culture 397 
Collection and authenticated by Bioidentity (www.http://bioidentity.es). Cells were cultured in 398 
Dulbecco's modified Eagle's medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum 399 
(FBS) (HyClone, Thermoscientific), and 1% penicillin-streptomycin (P/S) (Gibco). All cells were 400 
grown at 37°C, 5% CO2. Mycoplasma contamination analysis of the cells was performed by the Tissue 401 
culture core facility at the Universitat de València.  402 
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p53 reporter assay. HCT116 and A549 cells were transfected (Lipofectamine 2000) with a p53 404 
reporter plasmid (50) (Addgene plasmid 16442, http://www.addgene.org), a pRL-SV40 vector 405 
(Promega, http://www.promega.com; included to normalize the measurements), and a plasmid carrying 406 
the protein of interest. To induce p53 activation, 24 hrs after transfection, cells were either infected with 407 
Newcastle Disease virus (NDV) or were exposed to Doxorubicin (0.2 - 0.4 μM, Calbiochem, 408 
http://www.emdmillipore.com). Twenty-four hours later, cells were lysed and the luciferase signal from 409 
Firefly Renilla luciferase measured using a Dual-Luciferase Reporter Assay System (Promega, 410 
http://www.promega.com). NDV infections were as follows: twenty-four hours after transfection media 411 
was removed and the cells washed with PBS. Infection was with 200 µL of PBS/0.5% BSA with NDV 412 
at a MOI = 10. After a 1 hour incubation at room temperature, the virus was aspirated, and the cells 413 
washed with PBS. Fresh media was then added to the cells. 414 
 415 
Sub-cellular protein localization. For the co-localization study of PLRG1 and the Nipah virus W, V, 416 
and P proteins, HEK293T cells were seeded onto poly-Lys treated cover slips and, approximately 20-24 417 
hrs later, transfected with YFP-PLRG1 and either the P, V, or W (flag-tagged) constructs. After 24 hrs, 418 
cells were fixed (paraformaldehyde 4%, 20 min), permeabilized (0.1% Triton X-100) and washed (3x, 419 
PBS). Immunofluorescence was with a mouse anti-flag antibody (Sigma-Aldrich, 420 
www.sigmaaldrich.com); the secondary antibody was an anti-mouse Alexa 647 conjugate (Sigma-421 
Aldrich), with DAPI used to stain nuclei (Fluoroshield, Sigma-Aldrich). Images were captured using a 422 
FV1000 confocal microscope (Olympus, http://www.olympus-lifescience.com) at the microscopy core 423 
facility of the University of Valencia.  424 
 425 
Immunoprecipitation and immunodetection. Cells were transfected with the appropriated protein 426 
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(M, V or RFP) bearing the indicated antibody tag (HA or Flag). Approximately 48 hrs later, cells were 427 
lysed (20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM 428 
Sodium pyrophosphate, 1 mM Na3VO4, 1x Cocktail protease (Pierce)) on ice (5 min). Samples were 429 
centrifuged (10 min at 14,000 g) and the supernatant pre-cleared by a 30 - 60 min incubation (at 4 ºC) 430 
with protein A. Protein A was then pelleted by centrifugation (2,500 g 2-3min) and 1-10 μg of anti-431 
DICER1 antibody added to the clarified supernatant (Abcam Ab14601; incubated at 4 ºC overnight). 432 
Next, 20 μL of Protein A was added, and the samples incubated for 1 hr at 4ºC, then passed through a 433 
micro-spin column. Columns were washed (x3) with lysis buffer. Finally, samples were incubated with 434 
elution buffer (0.2 M glycine-HCl at pH 2.5) for 10 min at room temperature and then centrifuged (2 435 
min at 2,500 g). Flow-throughs were subject to western blot using either an anti-HA or an anti-Flag 436 
antibody (Sigma-Aldrich). For the identification of BCAS2, PRP19, and CDC5L, we used the 437 
WH0010286M1, SAB4501215, and HPA011361 antibodies, respectively (Sigma-Aldrich).  438 
 439 
DICER1 luciferase activity assay. To explore the activity of DICER1 in the presence of the Nipah 440 
virus W protein we used a luciferase assay based on miR124 processing. Briefly, a pBT plasmid 441 
expressing Gaussia luciferase containing four miR124 target sites was transfected into HEK293T cells 442 
together with a pEM plasmid containing miR124. An empty pEM plasmid was used as a negative 443 
control. Successful production of mature miR124 via DICER1 should block luciferase expression. 444 
Conversely, if DICER1 activity is diminished, the level of the luciferase signal should increase.  445 
 446 
RNAseq and analyses. Sequencing and sample preparation were completed at the Genomics Core 447 
facility at the University of Valencia. Prior to sequencing, the appropriate RNA quality was verified 448 
using a Bioanalyzer (Agilent, http://www.agilent.com) with the Agilent RNA 6000 Nano kit (used 449 
according to the manufacturer's instructions). RNA libraries were prepared using the TruSeq Stranded 450 
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mRNA sample preparation kit (Illumina, www.illumina.com) following the manufacturer's 451 
specifications. Sequencing was with an Illumina NextSeq5000 sequencer using the High Output kit 452 
(Illumina) (GEO accession number: SRP116105). Data analyses were with CuffDiff (53), EdgeR (54), 453 
and the DESeq2 (55) software.  454 
 455 
Acknowledgements 456 
We would like to thank to Drs. M. Shaw, CF Basler, BR tenOever, and BH Lee for plasmids and 457 
reagents. We thank Dr. A. Lamond for the YFP-PLRG1 construct. We also thank Dr. M Sanchez del 458 
Pino for his advice on the analysis of the proteomic data. The RNA sequencing was performed by the 459 
Genomics Core facility at the Universitat de València. This work was supported by grants from the 460 
Spanish Ministry of Economy and Competitiveness (MINECO) (grant no. BFU2016-79487), and from 461 
the Generalitat Valenciana (GV/2016/139, Program Grupos Emergentes; and PROMETEOII/2014/061, 462 
Program Grupos de Excelencia). LMG is funded by the Spanish MiNECO (Program Juan de la 463 
Cierva). 464 
 465 
LMG designed research; LMG and NMVV performed research; LMG and IM analyzed data and wrote 466 
the paper. 467 
 468 
The authors declare no competing financial interests. 469 
 470 
Bibliography471 
1.  Aguilar HC, Lee B. 2011. Emerging paramyxoviruses: molecular mechanisms and antiviral 
 on S
eptem



















strategies. Expert Rev Mol Med 13:e6. 
2.  Wong KT, Shieh WJ, Zaki SR, Tan CT. 2002. Nipah virus infection, an emerging paramyxoviral 
zoonosis. Springer Semin Immunopathol 24:215–228. 
3.  Lee KE, Umapathi T, Tan CB, Tjia HT, Chua TS, Oh HM, Fock KM, Kurup A, Das A, Tan AK, 
Lee WL. 1999. The neurological manifestations of Nipah virus encephalitis, a novel 
paramyxovirus. Ann Neurol 46:428–432. 
4.  Rockx B, Winegar R, Freiberg AN. 2012. Recent progress in henipavirus research: molecular 
biology, genetic diversity, animal models. Antiviral Res 95:135–149. 
5.  Escaffre O, Borisevich V, Rockx B. 2013. Pathogenesis of Hendra and Nipah virus infection in 
humans. J Infect Dev Ctries 7:308–311. 
6.  Clayton BA. 2017. Nipah virus: transmission of a zoonotic paramyxovirus. Curr Opin Virol 
22:97–104. 
7.  Luby SP, Hossain MJ, Gurley ES, Ahmed BN, Banu S, Khan SU, Homaira N, Rota PA, Rollin PE, 
Comer JA, Kenah E, Ksiazek TG, Rahman M. 2009. Recurrent zoonotic transmission of Nipah 
virus into humans, Bangladesh, 2001-2007. Emerg Infect Dis 15:1229–1235. 
8.  Negrete OA, Levroney EL, Aguilar HC, Bertolotti-Ciarlet A, Nazarian R, Tajyar S, Lee B. 2005. 
EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 
436:401–405. 
9.  Negrete OA, Wolf MC, Aguilar HC, Enterlein S, Wang W, Mühlberger E, Su SV, Bertolotti-
Ciarlet A, Flick R, Lee B. 2006. Two key residues in ephrinB3 are critical for its use as an 
alternative receptor for Nipah virus. PLoS Pathog 2:e7. 
10.  Dhondt KP, Mathieu C, Chalons M, Reynaud JM, Vallve A, Raoul H, Horvat B. 2013. Type I 
 on S
eptem



















interferon signaling protects mice from lethal henipavirus infection. J Infect Dis 207:142–151. 
11.  Satterfield BA, Cross RW, Fenton KA, Borisevich V, Agans KN, Deer DJ, Graber J, Basler CF, 
Geisbert TW, Mire CE. 2016. Nipah Virus C and W Proteins Contribute to Respiratory Disease in 
Ferrets. J Virol 90:6326–6343. 
12.  Basler CF. 2012. Nipah and hendra virus interactions with the innate immune system. Curr Top 
Microbiol Immunol 359:123–152. 
13.  Park M-S, Shaw ML, Muñoz-Jordan J, Cros JF, Nakaya T, Bouvier N, Palese P, García-Sastre A, 
Basler CF. 2003. Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist 
activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol 77:1501–1511. 
14.  Shaw ML. 2009. Henipaviruses employ a multifaceted approach to evade the antiviral interferon 
response. Viruses 1:1190–1203. 
15.  Ludlow LE, Lo MK, Rodriguez JJ, Rota PA, Horvath CM. 2008. Henipavirus V protein 
association with Polo-like kinase reveals functional overlap with STAT1 binding and interferon 
evasion. J Virol 82:6259–6271. 
16.  Rodriguez JJ, Parisien J-P, Horvath CM. 2002. Nipah virus V protein evades alpha and gamma 
interferons by preventing STAT1 and STAT2 activation and nuclear accumulation. J Virol 
76:11476–11483. 
17.  Rodriguez JJ, Cruz CD, Horvath CM. 2004. Identification of the nuclear export signal and STAT-
binding domains of the Nipah virus V protein reveals mechanisms underlying interferon evasion. 
J Virol 78:5358–5367. 
18.  Shaw ML, García-Sastre A, Palese P, Basler CF. 2004. Nipah virus V and W proteins have a 
common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear 
compartments, respectively. J Virol 78:5633–5641. 
 on S
eptem



















19.  Andrejeva J, Childs KS, Young DF, Carlos TS, Stock N, Goodbourn S, Randall RE. 2004. The V 
proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its 
activation of the IFN-beta promoter. Proc Natl Acad Sci U S A 101:17264–17269. 
20.  Childs K, Stock N, Ross C, Andrejeva J, Hilton L, Skinner M, Randall R, Goodbourn S. 2007. 
mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology 359:190–200. 
21.  Parisien J-P, Bamming D, Komuro A, Ramachandran A, Rodriguez JJ, Barber G, Wojahn RD, 
Horvath CM. 2009. A shared interface mediates paramyxovirus interference with antiviral RNA 
helicases MDA5 and LGP2. J Virol 83:7252–7260. 
22.  Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF. 2005. Nuclear localization of the Nipah 
virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling 
pathways. J Virol 79:6078–6088. 
23.  Bharaj P, Wang YE, Dawes BE, Yun TE, Park A, Yen B, Basler CF, Freiberg AN, Lee B, 
Rajsbaum R. 2016. The Matrix Protein of Nipah Virus Targets the E3-Ubiquitin Ligase TRIM6 to 
Inhibit the IKKε Kinase-Mediated Type-I IFN Antiviral Response. PLoS Pathog 12:e1005880. 
24.  Ding S, Mooney N, Li B, Kelly MR, Feng N, Loktev AV, Sen A, Patton JT, Jackson PK, 
Greenberg HB. 2016. Comparative Proteomics Reveals Strain-Specific β-TrCP Degradation via 
Rotavirus NSP1 Hijacking a Host Cullin-3-Rbx1 Complex. PLoS Pathog 12:e1005929. 
25.  Hirohata Y, Kato A, Oyama M, Kozuka-Hata H, Koyanagi N, Arii J, Kawaguchi Y. 2015. 
Interactome analysis of herpes simplex virus 1 envelope glycoprotein H. Microbiol Immunol 
59:331–337. 
26.  Sangsuriya P, Huang J-Y, Chu Y-F, Phiwsaiya K, Leekitcharoenphon P, Meemetta W, Senapin S, 
Huang W-P, Withyachumnarnkul B, Flegel TW, Lo C-F. 2014. Construction and application of a 
protein interaction map for white spot syndrome virus (WSSV). Mol Cell Proteomics MCP 
 on S
eptem




















27.  Tarassov K, Messier V, Landry CR, Radinovic S, Serna Molina MM, Shames I, Malitskaya Y, 
Vogel J, Bussey H, Michnick SW. 2008. An in vivo map of the yeast protein interactome. Science 
320:1465–1470. 
28.  Gloeckner CJ, Boldt K, Schumacher A, Roepman R, Ueffing M. 2007. A novel tandem affinity 
purification strategy for the efficient isolation and characterisation of native protein complexes. 
Proteomics 7:4228–4234. 
29.  Mellacheruvu D, Wright Z, Couzens AL, Lambert J-P, St-Denis NA, Li T, Miteva YV, Hauri S, 
Sardiu ME, Low TY, Halim VA, Bagshaw RD, Hubner NC, Al-Hakim A, Bouchard A, Faubert D, 
Fermin D, Dunham WH, Goudreault M, Lin Z-Y, Badillo BG, Pawson T, Durocher D, Coulombe 
B, Aebersold R, Superti-Furga G, Colinge J, Heck AJR, Choi H, Gstaiger M, Mohammed S, 
Cristea IM, Bennett KL, Washburn MP, Raught B, Ewing RM, Gingras A-C, Nesvizhskii AI. 
2013. The CRAPome: a contaminant repository for affinity purification-mass spectrometry data. 
Nat Methods 10:730–736. 
30.  Harcourt BH, Tamin A, Ksiazek TG, Rollin PE, Anderson LJ, Bellini WJ, Rota PA. 2000. 
Molecular characterization of Nipah virus, a newly emergent paramyxovirus. Virology 271:334–
349. 
31.  Horie R, Yoneda M, Uchida S, Sato H, Kai C. 2016. Region of Nipah virus C protein responsible 
for shuttling between the cytoplasm and nucleus. Virology 497:294–304. 
32.  Pentecost M, Vashisht AA, Lester T, Voros T, Beaty SM, Park A, Wang YE, Yun TE, Freiberg AN, 
Wohlschlegel JA, Lee B. 2015. Evidence for ubiquitin-regulated nuclear and subnuclear 
trafficking among Paramyxovirinae matrix proteins. PLoS Pathog 11:e1004739. 
33.  Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, Maciejewski A, Arndt D, Wilson M, 
 on S
eptem



















Neveu V, Tang A, Gabriel G, Ly C, Adamjee S, Dame ZT, Han B, Zhou Y, Wishart DS. 2014. 
DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42:D1091-1097. 
34.  Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. 
2006. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic 
Acids Res 34:D668-672. 
35.  Orchard S, Ammari M, Aranda B, Breuza L, Briganti L, Broackes-Carter F, Campbell NH, 
Chavali G, Chen C, del-Toro N, Duesbury M, Dumousseau M, Galeota E, Hinz U, Iannuccelli M, 
Jagannathan S, Jimenez R, Khadake J, Lagreid A, Licata L, Lovering RC, Meldal B, Melidoni 
AN, Milagros M, Peluso D, Perfetto L, Porras P, Raghunath A, Ricard-Blum S, Roechert B, Stutz 
A, Tognolli M, van Roey K, Cesareni G, Hermjakob H. 2014. The MIntAct project—IntAct as a 
common curation platform for 11 molecular interaction databases. Nucleic Acids Res 42:D358–
D363. 
36.  Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, 
Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von Mering C. 2015. STRING v10: 
protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43:D447-
452. 
37.  Pichlmair A, Kandasamy K, Alvisi G, Mulhern O, Sacco R, Habjan M, Binder M, Stefanovic A, 
Eberle C-A, Goncalves A, Bürckstümmer T, Müller AC, Fauster A, Holze C, Lindsten K, 
Goodbourn S, Kochs G, Weber F, Bartenschlager R, Bowie AG, Bennett KL, Colinge J, Superti-
Furga G. 2012. Viral immune modulators perturb the human molecular network by common and 
unique strategies. Nature 487:486–490. 
38.  Bauer A, Neumann S, Karger A, Henning A-K, Maisner A, Lamp B, Dietzel E, Kwasnitschka L, 
Balkema-Buschmann A, Keil GM, Finke S. 2014. ANP32B is a nuclear target of henipavirus M 
proteins. PloS One 9:e97233. 
 on S
eptem



















39.  Parvege MM, Rahman M, Nibir YM, Hossain MS. 2016. Two highly similar LAEDDTNAQKT 
and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine 
design against pathogenic Henipavirus. Comput Biol Chem 61:270–280. 
40.  Popa A, Carter JR, Smith SE, Hellman L, Fried MG, Dutch RE. 2012. Residues in the hendra 
virus fusion protein transmembrane domain are critical for endocytic recycling. J Virol 86:3014–
3026. 
41.  Bonaparte MI, Dimitrov AS, Bossart KN, Crameri G, Mungall BA, Bishop KA, Choudhry V, 
Dimitrov DS, Wang L-F, Eaton BT, Broder CC. 2005. Ephrin-B2 ligand is a functional receptor 
for Hendra virus and Nipah virus. Proc Natl Acad Sci U S A 102:10652–10657. 
42.  Sun W, McCrory TS, Khaw WY, Petzing S, Myers T, Schmitt AP. 2014. Matrix proteins of Nipah 
and Hendra viruses interact with beta subunits of AP-3 complexes. J Virol 88:13099–13110. 
43.  Ciancanelli MJ, Volchkova VA, Shaw ML, Volchkov VE, Basler CF. 2009. Nipah virus sequesters 
inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol 83:7828–7841. 
44.  Mahajan K. 2016. hPso4/hPrp19: a critical component of DNA repair and DNA damage 
checkpoint complexes. Oncogene 35:2279–2286. 
45.  Cheng SC, Tarn WY, Tsao TY, Abelson J. 1993. PRP19: a novel spliceosomal component. Mol 
Cell Biol 13:1876–1882. 
46.  Chanarat S, Seizl M, Sträßer K. 2011. The Prp19 complex is a novel transcription elongation 
factor required for TREX occupancy at transcribed genes. Genes Dev 25:1147–1158. 
47.  Xu Q, Wang F, Xiang Y, Zhang X, Zhao Z-A, Gao Z, Liu W, Lu X, Liu Y, Yu X-J, Wang H, Huang 
J, Yi Z, Gao S, Li L. 2015. Maternal BCAS2 protects genomic integrity in mouse early embryonic 
development. Dev Camb Engl 142:3943–3953. 
 on S
eptem



















48.  Chen P-H, Lee C-I, Weng Y-T, Tarn W-Y, Tsao Y-P, Kuo P-C, Hsu P-H, Huang C-W, Huang C-S, 
Lee H-H, Wu J-T, Chen S-L. 2013. BCAS2 is essential for Drosophila viability and functions in 
pre-mRNA splicing. RNA N Y N 19:208–218. 
49.  Kleinridders A, Pogoda H-M, Irlenbusch S, Smyth N, Koncz C, Hammerschmidt M, Brüning JC. 
2009. PLRG1 is an essential regulator of cell proliferation and apoptosis during vertebrate 
development and tissue homeostasis. Mol Cell Biol 29:3173–3185. 
50.  el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, 
Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 
75:817–825. 
51.  Hientz K, Mohr A, Bhakta-Guha D, Efferth T. 2017. The role of p53 in cancer drug resistance and 
targeted chemotherapy. Oncotarget 8:8921–8946. 
52.  Palese P, Shaw ML. 2007. Fields Virology. Orthomyxoviridae Viruses Their Replication 5th Edn 
Phila PA Lippincott Williams Wilkins Wolters Kluwer Bus 1647–1689. 
53.  Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for 
RNA-seq data with DESeq2. Genome Biol 15. 
54.  Robinson MD, McCarthy DJ, Smyth GK. 2010. edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics 26:139–140. 
55.  Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ, 
Pachter L. 2010. Transcript assembly and quantification by RNA-Seq reveals unannotated 
transcripts and isoform switching during cell differentiation. Nat Biotechnol 28:511–515. 
56.  Svobodova E, Kubikova J, Svoboda P. 2016. Production of small RNAs by mammalian Dicer. 
Pflugers Arch 468:1089–1102. 
 on S
eptem



















57.  Song M-S, Rossi JJ. 2017. Molecular mechanisms of Dicer: endonuclease and enzymatic activity. 
Biochem J 474:1603–1618. 
58.  Galluzzi L, Brenner C, Morselli E, Touat Z, Kroemer G. 2008. Viral control of mitochondrial 
apoptosis. PLoS Pathog 4:e1000018. 
59.  Rawling DC, Pyle AM. 2014. Parts, assembly and operation of the RIG-I family of motors. Curr 
Opin Struct Biol 25:25–33. 
60.  Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, Mann M. 2005. Exponentially 
Modified Protein Abundance Index (emPAI) for Estimation of Absolute Protein Amount in 
Proteomics by the Number of Sequenced Peptides per Protein. Mol Cell Proteomics 4:1265–1272.
 472 
Figure legends 473 
Figure 1. Affinity purification of Nipah virus proteins and analyses of MS data. (A) Flowchart of 474 
the TAP-MS approach used to identify Nipah virus-human interactions. hpt denotes hours post 475 
transfection. (B) The ave log (emPAI/med) of the 101 PPIs were grouped according to the number of 476 
times (replicates) they were found (2, 3, or 4). The single PPI found in 5 replicates was excluded from 477 
the representation. For each group, values for the number of interactors (top) and the averaged value of 478 
the ave log (emPAI/med) are shown. Those proteins found in 2 replicates were color-coded based on 479 
the TAP-tag position in the bait: blue, Nt; green, Ct; black (either Nt or Ct). The averaged values of the 480 
ave log (emPAI/med) of tag-position dependent (tpd) and independent (tpi) interactions are also 481 
indicated. (C) Influence of tag position on identification of the PPI. The number of interactors for each 482 
bait (Nipah virus proteins N, P, V, W, C, M, F, and G) are shown. Bars are color-coded according to the 483 
location of the tag. Gray indicates a host protein identified using a bait tagged at either terminus; blue 484 
indicates a protein that bound bait tagged at its N terminus (Nt) exclusively; green indicates the 485 
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opposite, an interaction between host protein and bait tagged exclusively at the C terminus (Ct). The 486 
pie chart above the bar graph indicates the percentage of interactors identified with Nt (blue), Ct 487 
(green), or Nt and Ct (gray) tagged baits. (D and E) Heat maps representing enriched cellular 488 
components (D) and biological processes (E) deduced from the human proteins captured with the 489 
Nipah virus baits. ER denotes Endoplasmic Reticulum. (F) The percentage of PPIs identified in the 490 
TAP-MS experiment that have been shown to be related (in the literature) to viral infection. 491 
Significance (Fisher test) was calculated using a random list of 101 proteins as a reference set.  492 
 493 
Figure 2. Network representation of TAP-MS-identified Nipah virus-human PPIs. A total of 126 494 
interactions (edges) and 93 proteins (nodes) are represented. Newly identified PPIs are indicated by 495 
solid black lines; previously described PPIs are those highlighted with a double solid line. Gray dotted 496 
lines indicate human-human PPIs obtained from the String and intACT databases. Nipah virus proteins 497 
are shown light red. Cellular proteins are shown either blue (Nt) or green (Ct) depending on the tag 498 
position (as described previously). Protein names (obtained from Uniprot) are provided within each 499 
node.  500 
 501 
Figure 3. Nipah virus proteins W and V interact with STAT4. (A) TAP of tagged V, W, VG121E, WG121E, 502 
and EYFP. Post purification, samples were immuno-blotted for STAT1, STAT4, and the FLAG tag.  (B) 503 
Network representation of the Nipah virus V and W interactions with STAT family members, as 504 
obtained in the TAP-MS experiments. TAP of tagged V, W, VG121E, WG121E and EYFP. After purification 505 
samples were probed against STAT1, STAT4 and FLAG.  506 
 507 
Figure 4. Interactions between the Nipah virus and the PRP19 complex. (A) Network 508 
representation of TAP-MS identified interactions between PRP19 complex members (gray nodes) and 509 
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Nipah virus proteins (red nodes). Solid black lines indicate interactions found in the TAP-MS 510 
experiments. Gray dotted lines represent PPIs identified in the String and intACT databases. (B). 511 
Average log(emPAI/median) value of the experimentally found interactions. Red dots highlight the 512 
PRP19 complex associated proteins. The dotted line indicates the average value for all samples. (C) 513 
Western blot identification of PRP19 complex members. Wildtype and mutant (G121E) V and W 514 
lysates, together with EYFP, were TAP purified and the final eluates immuno-blotted for CDC5L, 515 
PRP19, PLRG1, BCAS2, and the Flag tag. (D) Cellular localization of the V, W, and P proteins (red, 516 
immune-labeled) with YFP-PLRG1 (green). DAPI staining is shown as light gray. Co-localization of 517 
red and green channels is highlighted in yellow. Arrowheads indicate peri-nuclear regions where green 518 
and red co-localization was found.  519 
 520 
Figure 5. Nipah virus modulation of p53 activity. To investigate p53 activity in the presence of 521 
Nipah virus protein, a luciferase reporter plasmid was transfected into HCT116 cells (A-C) and A549 522 
(D-F). Post transfection cells were left untreated (Untreated) (A and D), were infected with Newcastle 523 
disease virus (NDV) (B and E) or were exposed to doxorubicin (Doxorubicin) (C and F). Luciferase 524 
values for control (untreated) cells transfected with the p53 reporter and EYFP were used to normalize 525 
the data (100%, dotted line, white bar panel A). Error bars indicate the standard deviation of at least 526 
three replicates. Significance (t-test) in each panel was calculated by comparison with values obtained 527 
with the Nipah virus W samples (black bar). *: p value<0.05, **: p value<0.01, ***: p value<0.001, ns: 528 
not significant. 529 
 530 
Figure 6. Nipah virus modulation of gene expression. (A) Flowchart representation of the mRNA 531 
extraction and purification protocol. (B) Pearson correlation analyses of the sequenced samples. This 532 
analysis included the expression profiles of all of the genes. (C) Venn diagram indicating the number of 533 
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differentially expressed genes when comparing Nipah virus W and luciferase samples, identified by 534 
CuffDiff (pink), DESeq2 (light blue), and EdgeR (yellow). (D) Heat map of the Log2RPM values for 535 
the 114 differentially expressed genes detected by all three algorithms. (E) qRT-PCR validation of RNA 536 
seq data. The bar graph shows the fold induction provoked by the expression of W protein over the 537 
luciferase values. Error bars represent the standard deviation of the three replicates. (F) qRT-PCR 538 
measurements of INHBA (red) and MUC19 (green) mRNAs, selected as example of genes down and up 539 
regulated, respectively, by the Nipah virus W protein. In these experiments cells were transfected with 540 
luciferase (reference sample) and expression plasmids for either the W or V proteins. After 48 hrs, 541 
mRNAs were extracted and measured by qRT-PCR. The bar graph shows the fold induction of mRNA 542 
achieved in the presence of either the W or V protein, over values recorded for luciferase. Error bars 543 
indicate the standard deviation of three replicates. Significance (t-test) was calculated by comparing the 544 
V and W samples. * denotes a p value <0.05 . (G) Average Log2 RPM for the Luc and W sample.  545 
 546 
Figure 7. Interaction of Nipah virus M with the DICER1-TARBP2 complex. (A) Network 547 
representation of the Nipah virus M protein interaction with cellular proteins. (B) Left panel, 548 
immunoprecipitation of endogenous DICER1 in HEK293T cells transfected with Nipah virus M and V 549 
protein (M-TAP and TAP-M and V-TAP) (TAP  tagged either at the amino terminus, TAP-M or the 550 
carboxilo end M-TAP and V-TAP). Middle and left panel show immunoprecipitation of endogenous 551 
DICER1 in HEK293T cells transfected with Nipah virus M and V protein and the RFP tagged with and 552 
HA flag in the indicated terminus. (C) DICER1 activity assay. HEK293T cells were transfected with 553 
luciferase (luc) plasmids containing mir124 target sites plus a plasmid expressing mir124. In the 554 
absence of mature miR124, expression of Luc is unhampered. Conversely, DICER1 dependent 555 
production of mature miR124 blocks Luc expression. The black bar indicates a negative control, 556 
comprising cells expressing Luc but no miR124 plasmid. White bars include EYFP (positive) and W 557 
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samples. A western blot was included to confirm the expression of EYFp and the Nipah virus M 558 
protein. (D) Northern blot of pre- and mature miR124 in cells expressing EYFP or the Nipah virus M 559 
























Table 1. Proteins identified by the TAP-MS              























     W O00505 KPNA3 Importin-alpha 3 3 0.75 1 2 1.59 22, 37 
     P O75934 SPF27 Pre-mrna-splicing factor spf27 4 1.00 2 2 1.43   
     P Q9UMS4 PRP19 Pre-mrna-processing factor 19 4 1.00 2 2 1.37   
     M Q92688 ANP32B Acidic leucine-rich nuclear phosphoprotein 32 2 0.50 1 1 1.28 38 
     W O00629 KPNA4 Importin subunit alpha-4 4 1.00 2 2 1.26 22, 37 
     W B2R7W3 BCAS2 Pre-mrna-splicing factor spf27 4 1.00 2 2 1.23   
     W Q9UMS4 PRP19 Pre-mrna-processing factor 19 4 1.00 2 2 1.19   
     P Q99459 CDC5L Cell division cycle 5-like protein 4 1.00 2 2 1.18   
     V B2R7W3 BCAS2 Pre-mrna-splicing factor spf27 3 0.75 1 2 1.08   
     V P52630 STAT2 Signal transducer and activator of transcription 2 2 0.50 1 1 0.98 16, 37 
     V Q9UMS4 PRP19 Pre-mrna-processing factor 19 4 1.00 2 2 0.94   
     P O43660 PLRG1 Pleiotropic regulator 1 4 1.00 2 2 0.89   
     C P40855 PEX19 Peroxisomal biogenesis factor 19  a 2 0.50 2 0 0.83   
     F Q53H37 CALM5 Calmodulin-like protein 5 2 0.40 0 2 0.80   
     C P35613 BSG Basigin/cd147emmpirin 3 0.75 2 1 0.80   
     V O43660 PLRG1 Pleiotropic regulator 1  2 0.50 0 2 0.79   
     F Q9Y5M8 SRPRB Signal recognition particle receptor subunit beta 3 0.60 1 1 0.78   
     N O75190 DNAJB6 Dnaj  subfamily b member 6 2 0.33 1 1 0.76   
     C Q9UHG3 PCYOX1 Prenylcysteine lyase 2 0.50 2 0 0.73   
     M P49458 SRP9 Signal recognition particle 9 kda protein 2 0.50 1 1 0.67   
     M A0A024R2I7 RAD18 Postreplication repair protein hrad18p 4 1.00 2 2 0.67 32 
     W O43660 PLRG1 Pleiotropic regulator 1 3 0.75 1 2 0.66   
     F I2G9F8 HLA-C Major histocompatibility complex, class I-c 3 0.60 2 1 0.62 39* 
     F P11441 UBL4A Ubiquitin-like protein 4a 4 0.80 2 1 0.59   
     P P51116 FXR2 Fragile x mental retardation syndrome related protein 4 1.00 2 2 0.55   
     V P42771 CDKN2A P16-ink4 2 0.50 1 1 0.48   
     N D3DR22 HSD17B12 Hydroxysteroid (17-beta) dehydrogenase 12 2 0.33 2 0 0.48   
     C O00161 SNAP23 Snap-23 2 0.50 2 0 0.47   
     M O15355 PPM1G Protein phosphatase 1g 4 1.00 2 2 0.47   
     V Q99459 CDC5L Cell division cycle 5-like protein 3 0.75 1 2 0.36   
     G P07203 GPX1 Glutathione peroxidase 2 0.40 1 1 0.33   
     N M4QFU4 HLA-B Mhc class i antigen 2 0.33 0 2 0.33 39* 
     M Q9UPY3 DICER1 Hypothetical helicase k12h4.8-like protein 2 0.50 0 2 0.30   
     M Q7Z6Z7 HUWE1 E3 ubiquitin-protein ligase huwe1 2 0.50 0 2 0.28   
     M Q8WVZ9 KBTBD7 Kelch repeat and btb domain-containing protein 7 2 0.50 1 1 0.27   
     W Q99459 CDC5L Cell division cycle 5-like protein 3 0.75 1 2 0.26   
     F A0A024RBE6 NAP1L1 Nucleosome assembly protein 1-like 1,  cra_b 2 0.40 0 2 0.25   
     M Q15633 TARBP2 Risc-loading complex subunit tarbp2  b 3 0.75 1 2 0.23   
     C Q9P0T7 TMEM9 Transmembrane protein 9 2 0.50 0 2 0.23   
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N O00217 NDUFS8 Nadh dehydrogenase  iron-sulfur protein 8 2 0.33 2 0 0.22   
     G Q15768 EFNB3 Ephrin-b3 2 0.40 2 0 0.19 32 
     C Q9H9H4 VPS37B Vacuolar protein sorting-associated protein 37b 4 1.00 2 2 0.19   
     V Q13126 MTAP Methylthioadenosine phosphorylase 3 0.75 1 2 0.18   
     F Q7L5D6 GET4 Cgi-20 protein 2 0.40 2 0 0.14   
     F A4D0U5 TES Testin  1 4 0.80 2 2 0.14   
     G Q9UK22 FBX2 F-box protein fbx2 5 1.00 2 2 0.13   
     N Q9Y4R8 TELO2 Kiaa0683 protein 2 0.33 1 1 0.12   
     F Q3SY69 ALDH1L2 Aldehyde dehydrogenase 1 family, member l2 2 0.40 1 1 0.09   
     M Q9UL15 BAG5 Bag family molecular chaperone regulator 5 2 0.50 1 1 0.06   
     P O43709 WBSCR22 Uncharacterized methyltransferase wbscr22  2 0.50 1 1 0.05   
     G P27544 CERS1 Ceramide synthase 1 2 0.40 2 0 0.05   
     G O60613 SEP15 Selenoprotein  1 precursor 2 0.40 2 0 0.05   
     C Q9BRK5 SDF4 Calcium-binding protein  1 precursor 2 0.50 0 2 0.03   
     F P51648 ALDH3A2 Fatty aldehyde dehydrogenase  2 3 0.60 1 1 0.03   
     F Q96AY3 FKBP10 Fk506-binding protein 2 0.40 2 0 0.01   
     N Q8NBQ5 HSD17B11 Unnamed protein product 3 0.50 1 2 0.01   
     P P52630 STAT2 Signal transducer and activator of transcription 2 2 0.50 1 1 0.01 16, 37 
     F P02786 TFRC Transferrin receptor protein 1 3 0.60 2 1 0.00 40** 
     G P52799 EFNB2 Ephrin-b2  2 0.40 2 0 -0.01 8, 41 
     M Q6PEV8 FAM199X Fam199x 2 0.50 0 2 -0.02   
     M Q9Y4B6 VPRBP Vprbp  1 3 0.75 1 2 -0.04 42 
     G Q9Y3A6 TMED5 Transmembrane emp24 protein transport 3 0.60 0 2 -0.06   
     F P46459 NSF Vesicle-fusing atpase 2 0.40 2 0 -0.09   
     C P51648 ALDH3A2 Fatty aldehyde dehydrogenase  2 2 0.50 1 1 -0.09   
     C Q9NV96 TMEM30A Cell cycle control protein 50a 2 0.50 0 2 -0.10   
     F Q9UNL2 SSR3 Translocon-associated protein subunit gamma 3 0.60 1 1 -0.10   
     W Q14765 STAT4 Signal transducer and activator of transcription 4 3 0.75 2 2 -0.10   
     P P56182 RRP1 Ribosomal Rna processing protein 1 2 0.50 1 1 -0.11   
     M Q9BTT0 ANP32E Acidic leucine-rich nuclear phosphoprotein 32 2 0.50 1 1 -0.12   
     C P25490 YY1 Transcriptional repressor protein yy1 2 0.50 0 2 -0.13   
     N Q9H078 CLPB Caseinolytic peptidase b 3 0.50 2 1 -0.14   
     N Q8WVC6 DCAKD Dephospho-coa kinase domain containing 3 0.50 3 0 -0.15   
     N O75306 NDUFS2 Nadh dehydrogenase-ubiquinone fe-s protein 2  3 0.50 1 2 -0.15   
     F Q7L099 RUFY3 Protein rufy3 2 0.40 0 2 -0.16   
    
 
G O15173 PGRC2 
Membrane-associated progesterone receptor 
component 2  
3 0.60 2 0 -0.16   
     F Q15165 PON2 Paraoxonase 2 2 0.40 2 0 -0.16   
     C Q9H4A5  GOLPH3L Golgi phosphoprotein 3-like 2 0.50 2 0 -0.16   
     M Q9GZU8 FAM192A Protein fam192a 3 0.75 2 1 -0.16   
     M A0A0C4DGV5Z RANB2 Zis1 4 1.00 2 2 -0.20   
     N P10155 TROVE2 Ro ribonucleoprotein 4 0.67 3 1 -0.21   
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M Q7Z4V5 HDGFRP2 Hepatoma-derived growth factor-related protein 2 2 0.50 1 1 -0.22   
     M Q96JK2 DCAF5 Ddb1- and cul4-associated factor 5 2 0.50 0 2 -0.22   
     C Q9ULX6 AKAP8L A-kinase anchor protein 8-like 2 0.50 1 1 -0.25   
     M Q96EY7 PTCD3 Pentatricopeptide repeat domain-containing protein 3 4 1.00 2 2 -0.25   
     C O95071 UBR5 E3 ubiquitin-protein ligase ubr5 2 0.50 0 2 -0.25   
     N Q8IWV7 UBR1 E3 ubiquitin-protein ligase ubr1 4 0.67 1 3 -0.26   
     M O00203 AP3B1 Ap-3 complex beta3a subunit 2 0.50 1 1 -0.29 42 
     M O43164 PJA2 Praja ring finger 2 3 0.75 1 2 -0.30   
     F Q8IXB1 DNAJC10 Hypothetical protein 2 0.40 1 1 -0.32   
     C Q8TEB1 DCAF11 Gl014 3 0.75 2 1 -0.32   
     C O43933 PEX1 Peroxisome biogenesis factor 1 2 0.50 0 2 -0.36   
     G Q9NRX5 SERINC1 Kiaa1253 protein 2 0.40 2 0 -0.38   
     N Q96AC1 FERMT2 Mitogen inducible gene mig-2 3 0.50 0 3 -0.39   
     C Q13557 CAMK2D Calcium/calmodulin-dependent protein kinase 2 delta 2 0.50 0 2 -0.39   
     M P30414 NKTR Nk-tumor recognition protein 2 0.50 1 1 -0.50   
     N A0A024RCG7 ARMCX2 Armadillo repeat containing 6 3 0.50 2 1 -0.54   
     N I0B0K5 FLG Truncated profilaggrin 2 0.33 1 1 -0.56   
     M P07199 CENPB Cenp-b 2 0.50 0 2 -0.62   
     N Q5VYK3 ECM29 Proteasome-associated protein ecm29  2 0.33 1 1 -0.67   
     F Q5T5U3 ARHGAP21 Rho-gtpase activating protein 10 2 0.40 1 1 -0.94   
     C Q92621 NUP205 Nuclear pore complex protein nup205 3 0.75 2 1 -0.97   
                          
      a Indicates the number of replicates in which the protein was found             
      b Number of replicates in which the protein was found/ total number of replicates performed with the indicated bait         
      c Indicates the number of replicates in which the protein was found with the Nt or Ct TAP-tag             
      d Proteins sorted based on the Ave log (empai/med)             
      * PPI reported with other Nipah virus protein             
      ** PPI reported with the equivalent Hendra virus protein               
























Table 2. List of drugs acting on potential Nipah virus 
      therapeutic targets     
               
     
 
Target DrugBank ID Drug group 
Acts 
on 










   
 
HLA-C DB02740 Experimental F 
     
 
ALDH1L2 DB00116 Approved F 
     
 
ALDH3A2 DB00157 Nutraceutical F 



















   
 
DB00997 Approved 





   
 
DB02158 Experimental 
   
 
DB02281 Experimental 
     
 
DB02282 Experimental 
     
 
DB02933 Experimental 
     
 
 
      
    
 
 
    
 
 Table 3. GO (Biological Process) of differentially expressed genes  
 Gene Set Name # 
Genes 
# Genes in 
overlap 
q-value  
 DNA Packing 194 17 9.58 e-21  
 Chromatin organization 663 21 3.42 e-17 
  Chromatin silencing 95 9 9.29 e-11 
  Innate Immune response in 
mucosa 
23 6 1.31 e-9 
  Defense response 1231 18 3.87 e-9 
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18 Nipah virus clones 
+ 5 Control clones
24-30 hpt 
cell lysis and clarification
Strep Tactin pull down, 






Agarose pull down, 
wash (x3) and elution 
with Flag peptide
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48 additional hrs 
of incubation
Transient transfection
 into 293-T cells
pIRES expressing EYFP 
and Luc or Nipah W
48 hpt, sorting of EYFP positive cells 
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